Overview

Effects of SQ109 on QTc Interval in Healthy Subjects

Status:
Withdrawn
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This will be a single center, open label, crossover study to evaluate the safety and tolerability of multiple dose levels of SQ109.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination